Fisher & Paykel Healthcare Corporation Limited (ASX:FPH)
Australia · Delayed Price · Currency is AUD | Market Cap | 17.26B -5.2% |
| Revenue (ttm) | 1.89B +14.2% |
| Net Income | 383.13M +144.8% |
| EPS | 0.65 +144.1% |
| Shares Out | n/a |
| PE Ratio | 45.05 |
| Forward PE | 41.38 |
| Dividend | 0.46 (1.56%) |
| Ex-Dividend Date | Dec 3, 2025 |
| Volume | 309,143 |
| Average Volume | 351,447 |
| Open | 29.30 |
| Previous Close | 29.23 |
| Day's Range | 29.12 - 29.39 |
| 52-Week Range | 29.03 - 35.31 |
| Beta | 0.91 |
| RSI | 33.39 |
| Earnings Date | May 25, 2026 |
About ASX:FPH
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilatio... [Read more]
Financial Performance
In fiscal year 2025, ASX:FPH's revenue was 2.02 billion, an increase of 15.96% compared to the previous year's 1.74 billion. Earnings were 377.20 million, an increase of 184.46%.
Financial numbers in NZD Financial StatementsNews
Fisher & Paykel Healthcare Corporation Earnings Call Transcript: H1 2026
First half revenue rose 14% to NZD 1.089 billion and net profit after tax increased 39% to NZD 213 million, with strong growth in both hospital and home care segments. Full-year guidance was raised, driven by FX and margin improvements, though H2 results may moderate due to seasonality and hardware sales variability.
Fisher & Paykel Healthcare Corporation Transcript: AGM 2025
Record revenue and profit growth were achieved, with ongoing investment in R&D and infrastructure. The Board emphasized long-term planning, addressed U.S. tariffs, and reaffirmed a 65% dividend payout target. All director elections and resolutions passed, supporting continued global expansion and innovation.
Fisher & Paykel Healthcare Corporation Earnings Call Transcript: H2 2025
Revenue grew 16% to NZD 2.02B and net profit rose 43% to NZD 377.2M, driven by strong hospital and home care growth, margin expansion, and new product launches. FY 2026 guidance anticipates continued revenue and profit growth, with gross margin improvement despite tariff headwinds.
Fisher & Paykel Healthcare Corporation Earnings Call Transcript: H1 2025
First-half revenue rose 18% and net profit after tax increased 43% year-over-year, driven by strong hospital and home care growth, new product launches, and improved margins. Full-year guidance remains unchanged, with expectations for continued growth and margin improvement.
Fisher & Paykel Healthcare Corporation Transcript: AGM 2024
Revenue and profit grew in FY24, with strong performance in both hospital and home care segments. Board succession and governance were highlighted, alongside infrastructure expansion and new product launches. Key risks addressed included climate, cybersecurity, and product recalls.